RLAY Q4 2025 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M

Gross Profit

$6M91.4% margin

Operating Income

-$61M-866.2% margin

Net Income

-$55M-784.1% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$621M

Total Liabilities

$54M

Stockholders' Equity

$567M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$0	—
Gross Profit	$6M	$0	—
Operating Income	-$61M	-$85M	+28.7%
Net Income	-$55M	-$76M	+27.8%